Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page
- Check3 days agoChange DetectedThe page no longer displays the condition 'Type 2 diabetes' and the related topic 'MedlinePlus Genetics'. This reduces visibility of the study's focus and related resources for users.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedAdded a new MedlinePlus Genetics topic covering Type 2 diabetes, expanding core content.SummaryDifference0.3%

- Check25 days agoChange DetectedUpdated page to v3.2.0 with a government operating status notice; removed the Type 2 diabetes MedlinePlus Genetics topic.SummaryDifference4%

- Check32 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision updated to v3.0.2 (replacing v3.0.1); the 'Back to Top' link/button was removed.SummaryDifference0.2%

- Check54 days agoChange DetectedThe web page has been updated to include information on Type 2 diabetes under MedlinePlus Genetics topics, and the version has been revised from v3.0.0 to v3.0.1.SummaryDifference0.5%

Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.